Search research articles
Contact Us
Filters
Showing results (141-150 of 187) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
Massimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
Andre Goy, Anas Younes, Peter McLaughlin, et al.
Blood Advances
|
July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy
Oluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Leukemia & Lymphoma
|
August 14, 2025
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents
Seda S Tolu, Caitlin Gribbin, Zhengming Chen, et al.
Leukemia & Lymphoma
|
June 7, 2026
Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center
Hua-Jay J Cherng, David DeStephano, Patrick Gould, et al.
Blood Advances
|
September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
Pamela B Allen, Xinyan Lu, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
Owen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
Issa F Khouri, Rima M Saliba, Chitra Hosing, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial
Jason R Westin, Michael A Thompson, Vince D Cataldo, et al.
Blood
|
February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
Anas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 187) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
Massimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
Andre Goy, Anas Younes, Peter McLaughlin, et al.
Blood Advances
|
July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy
Oluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Leukemia & Lymphoma
|
August 14, 2025
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents
Seda S Tolu, Caitlin Gribbin, Zhengming Chen, et al.
Leukemia & Lymphoma
|
June 7, 2026
Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center
Hua-Jay J Cherng, David DeStephano, Patrick Gould, et al.
Blood Advances
|
September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
Pamela B Allen, Xinyan Lu, Qing Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
Owen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
Issa F Khouri, Rima M Saliba, Chitra Hosing, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial
Jason R Westin, Michael A Thompson, Vince D Cataldo, et al.
Blood
|
February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
Anas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Page
of 19